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CD133/prominin-1 is a pentaspan transmembrane glycoprotein overexpressed in various solid tumours including colorectal and
glioblastomas. CD133 was found here to be highly expressed in X50% of pancreatic, gastric and intrahepatic cholangiocarcinomas.
Quantitative flow cytometric analysis showed that a panel of established hepatocellular, pancreatic and gastric cancer cell lines
expressed CD133 at levels higher than normal epithelial cells or bone marrow progenitor cells. A murine anti-human CD133
antibody (AC133) conjugated to a potent cytotoxic drug, monomethyl auristatin F (MMAF), effectively inhibited the growth of
Hep3B hepatocellular and KATO III gastric cancer cells in vitro with IC50 values of 2–7ngml
 1. MMAF induced apoptosis in the
cancer cells as measured by caspase activation. The anti-CD133-drug conjugate (AC133-vcMMAF) was shown to internalise and
colocalised with the lysosomal marker CD107a in the sensitive cell lines. In contrast, in the resistant cell line Su.86.86, the conjugate
internalised and colocalised with the caveolae marker, Cav-1. Addition of ammonium chloride, an inhibitor of lysosomal trafficking and
processing, suppressed the cytotoxic effect of AC133-vcMMAF in both Hep3B and KATO III. Anti-CD133-drug conjugate treatment
resulted in significant delay of Hep3B tumour growth in SCID mice. Anti-CD133 antibody-drug conjugates warrant further evaluation
as a therapeutic strategy to eradicate CD133þ tumours.
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Pancreatic, gastric and hepatocellular cancers are among the most
common forms of cancer of the digestive system with an estimated
incidence of approximately 38000, 22000, and 21000 cases in the
USA for 2008, respectively (Jemal et al, 2008). Hepatocellular
carcinomas, more common in Asia and sub-Saharan Africa, are
increasing in incidence in the USA. Both pancreatic and
hepatocellular cancers are fatal diseases, with the number of
deaths per year similar to the incidence, and an overall 5-year
survival of less than 5% in nonresectable cases. Worldwide, gastric
carcinoma is the third most common form of cancer with overall
5-year survival rates of less than 20% as most patients are
diagnosed late and are unsuitable for curative surgery. With the
challenge of disseminated disease at the time of diagnosis, there is
a critical need for finding more effective ways to eradicate the
cancer cells.
CD133, an antigenic marker for haematopoietic stem cells
(Miraglia et al, 1997; Yin et al, 1997), is expressed in several
haematopoietic malignancies including acute myelogenous leu-
kaemia (Horn et al, 1999), acute lymphocytic leukaemia (Buhring
et al, 1999), chronic lymphocytic leukaemia (Waller et al, 1999),
and myelodysplastic syndromes (Green et al, 2000). Additionally,
CD133 expression has been reported in several solid tumours
including retinoblastoma (Hemmati et al, 2003), glioblastoma
(Singh et al, 2003, 2004), prostatic adenocarcinoma (Collins et al,
2005; Rizzo et al, 2005), kidney carcinoma (Florek et al, 2005),
pancreatic cancer (Hermann et al, 2007) and colorectal cancers
(O’Brien et al, 2007; Van Orden et al, submitted). Significantly,
CD133-expressing cells in glioblastoma and colorectal cancers
include, but are apparently not limited to, the small subpopulation
of tumour cells termed cancer stem cells (CSCs) which mediate
tumour initiation and metastasis (Singh et al, 2004; O’Brien et al,
2007; Ricci-Vitiani et al, 2007). In addition to being considered the
tumour initiating cell population, cancer stem cells have also been
demonstrated to be insensitive to chemotherapy and radiation
treatment implying that they are responsible for tumour recur-
rence (Neuzil et al, 2007; Tang et al, 2007). For example, CD133-
positive glioma stem cells have been shown to mediate radiation
resistance in highly malignant gliomas (Bao et al, 2006).
Therapeutic targeting of CSCs populations through a molecule
such as CD133 therefore presents a novel opportunity to eradicate
tumour initiating, potentially drug-resistant cancer
subpopulations.
One goal of this study was to investigate the expression level of
CD133 in various solid tumours. Additionally we explored
antibody-drug conjugates (ADCs) as a therapeutic modality for
the selective targeting of CD133-expressing tumours. Recent
advances with ADCs using peptide linkers showed enhanced
efficacy and better specificity to antigen-expressing cells
(Dubowchik et al, 2002; Doronina et al, 2003, 2006). Specifically,
Received 1 May 2008; accepted 5 May 2008; published online 10 June
2008
*Correspondence: Dr LM Smith; E-mail: lsmith@seagen.com
3Current Address: deCODE Biostructures Inc., Bainbridge Island, WA,
USA.
4Current Address: MacroGenics Inc., Rockville, MD 20850, USA.
British Journal of Cancer (2008) 99, 100–109
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
san anti-human CD133 monoclonal antibody (MAb), AC133,
(Yin et al, 1997) was directly conjugated to the potent cytotoxic
drug, monomethyl auristatin F (MMAF) (Doronina et al, 2006),
using a valine-citrulline dipeptide linker that is cleavable by
proteases (Doronina et al, 2003). Our recent study using a panel of
normal and cancer tumour lines with varying levels of target
antigen demonstrated that the antigen density and trafficking to
the lysosomes are important factors for effective killing of the
target cells using an ADC (Smith et al, 2006). Indeed, we
demonstrated that it is possible to kill tumour cells that express
antigen at high levels while sparing normal cells expressing the
same antigen at a lower level. Here, we demonstrate effective in
vitro growth inhibition using an anti-CD133 ADC in CD133-
expressing hepatocellular carcinoma (Hep3B) and gastric carcino-
ma (KATO III) cell lines and significant delay of tumour growth in
vivo for Hep3B xenograft tumours in SCID mice.
MATERIALS AND METHODS
Cell lines and culture
Cell lines and the hybridoma AC133. 1 were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA)
and normal human primary cells (HREC, hepatocytes) were
obtained from Cambrex (Lonza, Switzerland) and AllCells
(Emeryville, CA, USA), respectively. Cell lines were cultured at
371C with 5% CO2 in ATCC-recommended media with 10% fetal
bovine serum (FBS) supplemented with 2mML -glutamine whereas
normal primary cells were grown in media recommended by the
suppliers. KATO III was grown in 20% FBS supplemented media.
Hybridoma AC133 was grown in hybridoma serum-free media
(Invitrogen, Rockville, MD, USA) supplemented with 2.5% FBS
and used for purification of MAb, AC133, for in vitro and in vivo
assays.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue microarrays were ob-
tained from commercial sources (TriStar, Rockville, MD; USBiomax,
Rockville, MD, USA; Imgenex, San Diego, CA, USA; and Petagen/
Abxis, Seoul, South Korea). These microarrays include cores
containing tumour tissues and corresponding normal tissues.
Slides were deparaffinised and processed for antigen retrieval
using EZ-retriever system (BioGenex, San Ramon, CA, USA).
Samples were preblocked with nonserum protein block (Dako A/S,
Glostrup, Denmark) and primary antibodies, used separately, were
incubated overnight at room temperature. MAb CD133/1 (AC133)
(Miltenyi, Auburn, CA, USA) and control MAb IgG were used at a
concentration of 5.0mgml
 1, whereas the anti-CD133 MAb, ab5558
(Abcam, Cambridge, MA, USA), was used at 2.5mgml
 1. Envision
Plus system HRP (Dako A/S) was used for detection with 3,3-
diaminobenzidine as the substrate for horseradish peroxidase.
Slides were then scored using a qualitative scoring scale based on
intensity (weak 1þ, mild 2þ, moderate 3þ, strong 4þ) and %
CD133þ cells (low¼o25%, moderate 25–75%, and high 475%).
Images were taken using a Zeiss Axiovert 200M microscope (Carl
Zeiss Microimaging, Thornwood, NY, USA). For mouse xenograft
tumours, a rabbit anti-CD133 MAb (Cell Signaling Technology,
Danvers, MA, USA) and a rabbit polyclonal anti-CD133 (ab19898,
Abcam) were used separately as primary antibodies and the Bond
Polymer Alkaline Phosphate (AP) Red Detection kit (Vision
BioSystems, Australia) for detection.
Quantitative flow cytometric analysis
Cell surface CD133 expression levels were quantified with QIFIKIT
flow cytometric indirect immunofluorescence assay (Dako A/S)
using CD133/1 as the primary antibody. A total of 5 10
5cells per
sample were incubated with a saturating concentration
(10mgml
 1) of primary antibody for 60min at 41C. After washes,
FITC-conjugated secondary antibody (1:50 dilution) was added
for 45min at 41C. Binding of antibodies was analysed by flow
cytometry and specific antigen density was calculated by
subtracting background antibody equivalent from antibody-
binding capacity based on a standard curve of log mean
fluorescence intensity vs log antigen-binding capacity.
Conjugation of antibodies
MAb AC133 in 50mM sodium borate, 50mM NaCl, and 1mM DTPA
pH 8.0 was partially reduced with 2.5 equivalents of Tris(2-
carboxyethyl)phosphine hydrochloride at 371C for 1h to yield
B5.3 thiols per antibody. The mixture was cooled to 01C and
partially reoxidised with 0.48 equivalents of 5,50-dithiobis-(2-
nitrobenzoic acid) to B4.4 thiols per antibody. This mixture was
reacted for 30min with 1.5 equivalents per thiol of maleimidoca-
proyl-valine-citrulline-p-aminobenzoyl-MMAF (vcMMAF) (Doro-
nina et al, 2006). Unreacted drug-linker was quenched with excess
N-acetyl-cysteine and the mixture purified on a centrifugal S-Fast
Flow cation exchange cartridge in 30mM sodium acetate (pH 5.0)
and eluted with PBS. For conjugation to a fluorophore, AC133 or
AC133-drug conjugates in 50mM sodium borate, 50mM NaCl pH
8.0 were reacted with 6.0 equivalents of Alexa Fluor 488 or 594
N-hydroxysuccinimide ester (Invitrogen) at 251C for 1h. Con-
jugates were purified on PD-10 columns equilibrated with PBS.
Cytotoxicity assay
Cytotoxicity was measured using a resazurin (Sigma, St. Louis,
MO, USA) dye reduction assay (McMillian et al, 2002). Briefly, cells
were plated at 3000 cells per well in 96-well plates, then fresh media
was added with or without ADC or AC133 with cross-linking
secondary antibody (twofold excess). For inhibition of lysosomal
trafficking and processing, Hep3B and KATO III cells were
preincubated with 0, 5 or 10mM ammonium chloride (Sigma,
St Louis, MO, USA), a lysosomotrophic agent (Sutherland et al,
2006), 30min prior to incubation with the ADCs. Resazurin was
added to cells to a final concentration of 50mM after 72–96h of
exposure to MAb or ADC. Cells were incubated for 2–6h,
depending on dye conversion of cell lines, and dye reduction
was measured on a Fusion HT plate reader (Packard Instruments,
Meridien, CT, USA) with excitation and emission wavelengths of
530 and 590nm, respectively. The IC50 value is defined here as the
drug concentration that results in 50% reduction in growth or
viability as compared with untreated control cultures.
Cell proliferation assay
Cells were plated, grown and treated as for the cytotoxicity assay in
96 well plates. After 96h of treatment, 0.5mCiwell
 1 of [
3H]-
thymidine (PerkinElmer, 6.7Cimmol
 1) was added to cells and
incubated for 6h at 371C and 5% CO2. To lyse cells, plates were
frozen overnight at  201C and then cell lysates were harvested
using FilterMate (Packard Instruments) into 96 well filter plates.
Radioactivity associated with cells was measured on the TopCount
(Packard Instruments) scintillation counter.
Measurement of apoptosis
Hep3B cells were plated in 96-well plates at a density of 3000 cells
per well in complete media. After 24h, ADCs were added in
increasing concentrations and cells were incubated for 24–72h.
An equal volume of Caspase-Glo 3/7 reagent (Promega, Madison,
WI, USA) was added at each time point and plates were read using
a Fusion HT plate reader (Packard Instruments, Meridien, CT,
CD133 in hepatocellular and gastric cancers
LM Smith et al
101
British Journal of Cancer (2008) 99(1), 100–109 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sUSA) after 1h. Caspase activity of test samples were calculated as a
percentage of caspase activity in untreated control cells.
Immunofluorescence
Cells were grown in coverslip-bottom chamber slides to about 75%
confluence. ADC directly conjugated to Alexa Fluor 488 or 594
were added to the cells at 1.0mgml
 1. After 24h cells were fixed
and permeabilised with paraformaldehyde/saponin as provided in
the Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA, USA) and
then stained with mouse anti-CD107a-FITC (lysosomal marker)
(BD Biosciences) or anti-Caveolin-1-Cy5 (Sigma). Nuclei were
stained using 4,6-diamidino-2-phenylindole (DAPI, Roche,
Switzerland). Cells were mounted with Prolong antifade reagent
(Invitrogen). Images were obtained using the Zeiss Axiovert 200M
under oil immersion 63  objective with apotome for optical
sectioning.
In vivo efficacy study
Severe combined immunodeficient mice (SCID, Harlan, Indiana-
polis, IN, USA) were implanted subcutaneously with 1 10
7
Hep3B cells (ATCC) grown in Minimum Essential Medium Eagle
medium (ATCC 30-2003), complemented with of 1% Pen/Strep
and 10% FBS. Tumour-bearing mice were randomly divided into
groups of seven animals when the mean tumour volume was
100mm
3. Mice were then treated by intraperitoneal injection every
4 days for a total of 4 doses with either the anti-CD133 MAb,
AC133 at 10mgkg
 1, or the corresponding antibody-drug
conjugate, AC133-vcMMAF at 1.0 or 3.0mgkg
 1, or MOPC21-
vcMMAF, at 1.0 or 3.0mgkg
 1. MOPC21 (ATCC) was used as
nonbinding isotype-matched (IgG1) control MAb to AC133. An
additional group of tumour-bearing mice was left untreated as a
control. Tumour size was measured two times weekly using
calipers. Tumour volume was calculated using the formula,
(A B
2)/2, where A and B are the largest and second largest
perpendicular tumour dimensions, respectively. Animals were
euthanised when tumours reached a volume of 1000mm
3 or at the
end of the study. Tumours were collected for further analysis of
CD133 expression by flow cytometry or immunohistochemistry.
For statistical analysis of efficacy data, the log-rank (Mantel–
Cox) test was applied using Prism 5.0 (GraphPad Software) to
analyse the differences in median tumour quadrupling time
between groups. Differences were judged to be significant if
Pp0.05. Tumour quadrupling times were determined by nonlinear
regression analysis for exponential growth for each experimental
animal. Animals that did not reach the quadrupling end point were
assigned a quadrupling time as the last day of the study. Actual
tumour sizes were used in plotting the data using Prism 5.0. All
animal procedures were performed under a protocol approved by
the Institutional Animal Care and Use Committee in a facility
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care.
RESULTS
CD133 is highly expressed in pancreatic, gastric, and
hepatocellular carcinomas
To determine the expression of CD133 in various solid tumours,
two MAbs were used separately for the detection of CD133 in
formalin-fixed paraffin-embedded samples by immunohisto-
chemistry. An initial survey was conducted with a multi-cancer
tissue microarray comprising 12 representative samples from each
organ/tissue tumour type: lung, breast, ovary, colon, melanoma,
pancreatic, kidney, head and neck, liver, and prostate. Several
tumour types were identified with weak to strong staining
including hepatocellular carcinomas (12 out of 12 samples) and
pancreatic adenocarcinomas (4 out of 12 samples). Additional
samples for each tumour type were studied using tissue micro-
arrays specific for pancreatic, gastric, renal, prostatic and
hepatocellular cancers. The intensity of the staining for CD133
ranged from weak (1–2þ) to strong (3–4þ) (Figure 1A–C).
Close concordance was observed between the reactivity of both
anti-CD133 MAbs in formalin-fixed tissues for most tumour types,
with somewhat more variability observed for kidney and prostate
cancers (Table 1). The immunostaining pattern was characterised
by membranous (apical) as well as luminal staining of the gland-
like tumour structures. The apical and luminal pattern of
expression is also highly characteristic of the CD133 staining
pattern observed in other solid tumours such as colorectal cancers
(Figure 1A–C). The nature of the luminal staining is not known,
and may represent sloughed cells and/or extracellular membrane
particles that contain CD133. However, the staining was CD133
specific, as judged by concordant reactivity between the two anti-
CD133 MAbs used and the absence of staining with an isotype-
matched negative control MAb.
A high percentage of tumour samples were found to be positive
for CD133 in gastric (47–55%), pancreatic (55–68%), and
cholangiocarcinomas (67%, biliary type of liver cancer) (Table 1)
with the percentages reported based on the analysis using the two
MAbs. Qualitative evaluation of the cancer cells within each
tumour core showed that gastric carcinomas generally had
moderate (25–75%) to high (475%) percentage of CD133þ
while pancreatic and hepatocellular/cholangiocarcinomas cases
have generally low (o25%) to moderate % CD133þ tumour cells
with some rare high percentage cases. CD133 expression was also
detected in 10–38% of renal cell carcinoma cases. Metastatic
tumours (20–30 cases primarily of gastric and colorectal origin)
included in the gastric and liver tissue microarrays also showed a
high percentage (X50%) of CD133 positivity, with similar strong
membranous and apical pattern of expression (Figure 1). When
tumour grades were available, correlation to CD133 immunostain-
ing intensity, distribution or tumour type was evaluated. No
significant association with tumour stage or grade was observed
for any of the tumour types evaluated with the caveat that a limited
number of cases were studied.
CD133 expression in corresponding normal tissues included
in the tissue microarrays was also analysed (Figure 1D–F).
Weak apical membrane staining was detected in biliary ducts of
liver (Figure 1D), pancreatic acinar and ductal epithelium
(Figure 1E), and gastric glandular crypt epithelium tubular
(Figure 1F). Apical membranous, and, to a lesser degree
cytoplasmic, immunostaining was also observed multifocally in
normal renal tubular epithelium, glomerular parietal epithelium,
and urothelium with each of the anti-CD133 mAbs (data not
shown). Thus, CD133 expression levels in these normal tissues are
lower than in tumours.
Anti-CD133 ADCs are potent inhibitors of cell
proliferation of Hep3B and KATO III cells
Hepatocellular, pancreatic and gastric cancer cell lines expressing
CD133 were identified by quantitative FACS (Table 2). The cell
lines used in this study showed a mono-modal flow cytometry
profile indicating relatively homogenous expression of CD133. The
highest CD133 expression was observed for the hepatocellular cell
line, Hep3B with 66000 sites per cell, followed by the pancreatic
cell lines Su.86.86 at 36000 sites per cell and CAPAN-1 at 30000
sites per cell. The other hepatocellular, pancreatic and gastric
cancer cell lines evaluated had lower CD133 expression levels of
6500–12000 sites per cell. In addition, normal renal epithelial cells
and hepatocytes were also tested and displayed minimal to no
detectable CD133 expression while we previously determined that
CD34-enriched normal bone marrow progenitor cells have o5000
CD133 sites per cell (Van Orden et al, 2008).
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sTable 1 CD133 expression analysis by immunohistochemistry
CD133
+ cases: ab5558, AC133 (n)
Tumour type Total cases (n) 1–2+ 2–3+ 3–4+ Total CD133
+ cases: ab5558, AC133 (%)
Primary tumours
Gastric adenocarcinomas 60 25, 22 2, 6 6, 0 55, 47
Pancreatic ductal adenocarcinomas 31 13, 15 8, 2 0, 0 68, 55
Kidney and urothelial carcinomas 29 6, 1 5, 2 0, 0 38, 10
Intrahepatic cholangiocarcinomas 12 7, 8 1, 0 0, 0 67, 67
Prostatic adenocarcinomas 39 6, 2 2, 2 0, 0 20, 5
Metastatic tumours
Liver
a 30 7, 10 6, 4 1, 5 47, 63
Gastric 20 6, 6 1, 4 3, 0 50, 50
CD133 expression in solid carcinomas was analysed using tissue microarrays and anti-CD133 MAbs, ab5558 and AC133 and then scored based on the intensity of staining
(1–4+, see Figure 1(A–C).
aPredominantly colonic in origin.
Pancreatic adenocarcinoma
Cholangiocarcinoma Normal liver
Gastric adenocarcinoma Normal stomach
Normal pancreas
1-2+
2-3+
3-4+
50 µm 50 µm
50 µm 50 µm
50 µm 50 µm
Figure 1 Immunohistochemical analysis of CD133 expression demonstrating the scoring intensity and expression pattern. Representative images using
anti-CD133 MAb ab5558: (A) liver cholangiocarcinoma with multifocal, minimal to mild membranous and cytoplasmic staining, (B) pancreatic
adenocarcinoma with mild to moderate membranous (apical) staining of luminal structures, (C) gastric adenocarcinoma with moderate to strong staining in
two distinct cell populations: (1) luminal and apical and (2) cytoplasmic and membranous, (D) normal liver with minimal and nonspecific cytoplasmic staining
of hepatocytes and apical staining of bile duct, (E) normal pancreas with weak to mild, apical membranous staining of acinar epithelium and ductal epithelium,
(F) normal stomach with minimal to mild apical staining of glandular crypt epithelium. The scale bars represent 50mm.
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sAnti-CD133 MAb, AC133 (Yin et al, 1997) was conjugated to the
anti-tubulin drug, vcMMAF (Doronina et al, 2006), with a mean
stoichiometry of four drugs per antibody. The resultant ADC,
referred to hereafter as AC133-vcMMAF, had potent cytotoxic
activity against Hep3B and KATO III cell lines as demonstrated by
IC50 values ranging from 5–10ngml
 1 in a resazurin dye
conversion assay (Figure 2A). In contrast, AC133-vcMMAF had
minimal cytotoxic activity (IC50 X10mgml
 1) against the other
cells tested: HepG2, AGS, Su.86.86, Capan-1 and normal renal
epithelial cells and hepatocytes (Table 2). The positive control
ADC, OKT9-vcMMAF, targeting the transferrin receptor, was
cytotoxic against all cell lines tested (IC50 values of 50–
100ngml
 1, Figure 2A and B). Unconjugated antibody (AC133)
cross-linked to a secondary antibody did not exhibit in vitro
cytotoxic activity (Figure 2A). When cell proliferation was
measured by [
3H]-thymidine incorporation, potent growth inhibi-
tion by AC133-vcMMAF was observed for both Hep3B and KATO
III cell lines, with IC50 values of 2 and 7ngml
 1, respectively
(Figure 2B and Table 2).
To verify that the mode of cell killing by the anti-CD133-drug
conjugate is by induction of apoptosis, as observed for other
auristatin-containing ADCs (Francisco et al, 2003; Law et al, 2004,
2006; Sutherland et al, 2006), measurement of apoptotic cells were
done at several time points after treatment of the cells. The
percentage of apoptotic cells relative to untreated cells was
measured using a caspase 3/7 activation assay. Apoptotic cells
were detected by 48h with peak caspase activation by 72h
(Figure 2C). Results are shown for Hep3B cells treated with
increasing concentration of AC133-vcMMAF and OKT9-vcMMAF,
a positive control ADC, and the negative isotype control ADC
(mouse IgG-vcMMAF). At 72h after ADC treatment, maximal
caspase activity is observed at 10ngml
 1 concentration of AC133-
vcMMAF whereas the positive control OKT9-vcMMAF required a
higher concentration (400ngml
 1), concordant with the efficacy of
the ADCs as measured by cytotoxicity assay (Figure 2A).
Subcellular localisation of anti-CD133 ADC in sensitive
and resistant cancer cell lines
Cells grown in chamber slides were treated with anti-CD133 ADC.
A FITC-conjugated anti-CD107a was used to investigate the
colocalisation of the ADC (red fluorescence) with the lysosomal
marker (green fluorescence) at 24h (Figure 3A). Lysosomes are
rich in proteases such as cathepsin B necessary for effective
cleavage and release of the drug from the antibody. Images taken
using optical sectioning showed overlap in the fluorescence signal
(yellow in the merged image) in Hep3B, indicating colocalisation
of the internalised AC133-vcMMAF with the lysosomal marker.
Similar colocalisation was seen with KATO III cells, albeit with
much lower overall ADC accumulation. In contrast, for the ADC-
resistant cell line Su.86.86, colocalisation of the ADC was observed
with a caveolae marker Cav-1, but not with the lysosomal marker,
CD107a (Figure 3B).
To verify that lysosomal trafficking and processing is required
for the ADC efficacy, cytotoxicity experiments were conducted in
the presence or absence of ammonium chloride (NH4Cl), a
lysosomotropic agent that disrupts trafficking and lysosomal
processing by neutralising the acidic environment of the
endosomal/lysosomal compartments (Fredericksen et al, 2002;
Sutherland et al, 2006). Hep3B cells were preincubated with NH4Cl
(5 or 10mM) before addition of 400ngml
 1 anti-CD133 ADC and
controls. At this concentration we observed maximal cytotoxicity
in Hep3B (Figure 2A). As shown in Figure 2C, addition of NH4Cl
inhibited cytotoxicity of both AC133-vcMMAF and the positive
control ADC (OKT9-vcMMAF) in Hep3B cells. The same
protective effect of addition of NH4Cl on ADC activity was
observed in KATO III cells (data not shown). Dose-dependent
effect of NH4Cl showed a significant difference between AC133-
vcMMAF and negative control ADC (IgG-vcMMAF), although
some nonspecific inhibitory effect of higher concentration of
NH4Cl (10mM) is observed with the negative control (Figure 2D).
These data imply that lysosomal trafficking and processing is one
of the important factors for the activity of the anti-CD133-drug
conjugate. Other factors, such as intracellular drug concentration
and cysteine protease metabolism, impact the overall efficacy of
the ADC.
In vivo ADC efficacy study using Hep3B tumours
The potent in vitro cytotoxic activity of the anti-human CD133
ADC, AC133-vcMMAF, against Hep3B cells prompted us to
evaluate the in vivo antitumour activity of this ADC against
Hep3B xenografts. First, expression of CD133 in Hep3B tumour
xenografts was verified by both flow cytometry (not shown) and
IHC (Figure 4B). Efficacy experiments were then performed using
SCID mice with established (B100mm
3) subcutaneous Hep3B
tumours. Mice were treated by intraperitoneal injection with
multiple doses (every 4 days for a total of 4 doses) AC133-vcMMAF
or an isotype control mouse IgG1-vcMMAF, both as
4-drug loaded ADCS or alternatively with the unconjugated parent
MAb, AC133. Mice treated with AC133-vcMMAF at 3.0mgkg
 1
showed pronounced anti-tumour response with 2 out of 7
Table 2 Tumour and normal cell line expression of CD133 and sensitivity to anti-CD133 antibody-drug conjugate, AC133-vcMMAF
Cell line CD133 copies per cell
a Cytotoxicity IC50 (ngml
 1)
b Growth inhibition IC50 (ngml
 1)
b
Hepatocellular
Hep3B 66000 5.2±1.0 2.2±0.8
HepG2 10000 410000 410000
Gastric
KATO III 12000 9.5 7.0
AGS 6500 10000 10000
Pancreatic
Su.86.86 36000 410000 410000
Capan-1 30000 410000 410000
Normal cells
Renal epithelial 800 410000 410000
Hepatocytes Not detected 410000 Not tested
aCD133 expression was estimated by quantitative FACS.
bIC50 values (mean±s.e.m.) were calculated as described in Materials and methods from X3 or more independent
experiments, except for KATO III (n¼2).
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scomplete responses and 3 out of 7 partial responses and an overall
delay in tumour growth (Figure 4A). Tumour volume data were
plotted until one or more of the mice in each treatment group
(n¼7) died or was euthanised. Remaining AC133-vcMMAF-
treated mice were followed up to day 59 and remaining tumours
were collected for analysis of CD133 expression by IHC. Log-rank
test of tumour quadrupling time showed a significant difference
(P¼0.0001) in the growth of Hep3B tumours treated with AC133-
vcMMAF (3.0mgkg
 1) compared to control IgG-vcMMAF at the
same dose. In contrast, the naked AC133 antibody (10mgkg
 1),
AC133-vcMMAF at 1.0mgkg
 1 or the control ADC (1.0 or
3.0mgkg
 1) exhibited little or no anti-tumour activity. The anti-
CD133 ADC, AC133-vcMMAF, was well tolerated at efficacious
doses and no overt signs of toxicity were observed. MAb
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Figure 2 Activity of anti-CD133 ADC against cancer cell lines. (A) ADCs targeting CD133 have potent cytotoxic activity against antigen-positive
hepatocellular and gastric carcinoma cell lines. Cytotoxicity was measured by resazurin dye conversion in Hep3B and KATO III cells grown in 96-well plates
and exposed to anti-CD133 (AC133-vcMMAF) and control ADCs (IgG-vcMMAF and OKT9-vcMMAF) and crosslinked unconjugated anti-CD133 MAb
(AC133) for 96h. (B) Proliferation was measured using [
3H]-thymidine uptake in Hep3B and KATO III cells grown in 96-well plates and exposed to anti-
CD133 and control ADCs for 96h. (C) Induction of apoptosis in Hep3B cells treated with AC133-vcMMAF. Caspase 3/7 activation, a quantitative
measurement of apoptotic cells, was monitored using the Caspase Glo assay at various time points (24–72h) after addition of ADCs. Caspase 3/7 activation
relative to untreated cells was detected by 48h with optimal measurement after 72h in Hep3B cells treated with increasing concentrations of AC133-
vcMMAF and positive control OKT9-vcMMAF. (D) Inhibition of ADC cytotoxicity using internalisation inhibitor, ammonium chloride (NH4Cl) in Hep3B
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 1 is shown.
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(antigen-dependent) toxicities were not evaluated in these
xenografts experiments.
To determine whether CD133-expressing tumour cells are
present in the Hep3B tumours that developed after treatment with
AC133-vcMMAF, immunohistochemical analysis was performed
using a rabbit MAb that binds to the third extracellular domain of
CD133 (Figure 4B) and a rabbit polyclonal Ab generated against a
different epitope within the intracellular C terminus (data not
shown). Mice that responded with a tumour growth delay
following AC133-vcMMAF treatment showed low levels of expres-
sion of CD133 within their tumours (Figure 4B-c) indicating either
elimination of most CD133þ tumour cells or downregulation of
CD133. In contrast, higher levels of CD133 were observed in
tumours from mice that were untreated (Figure 4B-a) or treated
with a nonbinding control ADC (red stain, Figure 4B-b).
Concordant staining was observed with both anti-CD133 rabbit
antibodies used, indicating that detection of CD133 in the tumour
xenografts was not blocked by ADC treatment.
DISCUSSION
Our initial observation of CD133 overexpression in colorectal
tumours led us to study other tumour types where CD133 may
have a potential role in tumour formation. We performed a survey
of various tumours and found significant expression of CD133 in
pancreatic, gastric, and liver tumours. Metastatic gastric and liver
tumours were also found to be CD133-positive indicating that
expression is maintained in secondary tumours.
CD133 has been identified as a cancer stem cell marker in brain
(Singh et al, 2003, 2004), prostate (Collins et al, 2005), colorectal
(O’Brien et al, 2007; Ricci-Vitiani et al, 2007) and pancreatic
(Hermann et al, 2007) cancers. Cancer stem cells are defined as
those cells within a tumour that possess the capacity to self-renew
and to give rise to the heterogeneous lineages of cancer cells that
comprise the tumour (Clarke et al, 2006). Strong evidence for the
existence of cancer stem cell populations in acute myelogenous
leukaemia (Bonnet and Dick, 1997) has invigorated the study of
cancer stem cells in both haematologic and solid tumours (Clarke
et al, 2006). The concept of cancer stem cells implies that these
cancer-initiating cells are a critical population that need to be
eliminated for cures (Jones et al, 2004; Jordan, 2005; Huff et al,
2006; Jin et al, 2006). On the basis of our studies and other
published reports (O’Brien et al, 2007; Ricci-Vitiani et al, 2007),
the proportion of CD133-positive cells is highly variable (up to
25%) across these tumour types. Moreover, not all CD133-positive
cells are capable of initiating tumours in vivo. Flow cytometry
analysis showed that the cell lines studied here have a mono-modal
expression of CD133, albeit at different levels for each cell line. For
consistent growth of tumours in vivo, it required at least 1 10
7
Hep3B cells to be implanted in SCID mice. Thus, CD133 expression
is not restricted solely to the cancer stem cells.
In tumour types where CD133 expression is restricted to the
putative cancer stem cell subpopulation, tissue microarrays with
their limited tumour area for analysis may not provide a
representative view of CD133 expression. In hepatocellular, gastric
and pancreatic tumours that we analysed using tissue microarrays,
we observed a greater percentage of tumour cells that are CD133-
positive. As for the cell lines studied, they also strongly suggest
that CD133 expression in these tumour types is not limited to the
putative cancer stem cells. Larger tissue sections, as compared
to tissue microarrays, may increase the likelihood of detecting
CD133 expression in cases where the frequency of antigen-positive
ADC
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Figure 3 Subcellular localisation of anti-CD133 ADC, AC133-vcMMAF, in sensitive and resistant cancer cell lines. (A) AC133-vcMMAF, partially
colocalises (yellow) with the lysosomal marker, CD107a, in Hep3B and KATO III cells. Subcellular localisation of AC133-vcMMAF (red) and CD107a (green)
in Hep3B and KATO III cells after 24h incubation with the ADC. (B) Subcellular localisation of AC133-vcMMAF, lysosomal marker, CD107a, and caveolin-1
(Cav-1) in Su.86.86 after 24h incubation with the ADC. AC133-vcMMAF colocalises with Cav-1 (yellow) and not with CD107a in this resistant cell line.
Nuclei were stained blue with DAPI. Images were acquired using a  63 oil immersion objective with Apotome for optical sectioning.
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stumour cells is low. Good concordance using two different
anti-CD133 MAbs for the IHC analysis and staining pattern
(membranous, apical and luminal) strongly supports the
validity of the results obtained here for the expression profiling
of CD133.
Apical staining for CD133 is as expected based on the biology of
the molecule but the luminal staining in tumours is a novel
observation. The nature of the luminal staining for CD133 in
primary tumours as well as in the Hep3B in vivo model is
unknown. Weak, homogeneous staining of luminal necrotic debris
and secretory material is often observed in immunohistochemical
procedures, and is generally considered nonspecific. In these
tumour tissues, however, the luminal immunostaining of sloughed
cells and unidentified material was consistently associated with
specific staining of tumour cells lining the lumen and of strong
intensity that is considered specific. Release of extracellular
membrane particles containing CD133 has been reported in neural
progenitor cells and some epithelial cells (Marzesco et al, 2005). To
our knowledge such particles have not yet been reported for
tumour cells, although the luminal staining that observed here is
consistent with this notion. Using CD133þ tumour cell lines
grown in vitro, released CD133 was not detected in the culture
media. Flow cytometric analysis of dissociated cells from in vivo
tumours confirmed that CD133 expression is on the cell surface
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Figure 4 In vivo efficacy of an anti-CD133 ADC in Hep3B hepatocellular carcinoma model including IHC analysis of CD133 expression following ADC
treatment. (A) In vivo efficacy of AC133-vcMMAF in Hep3B subcutaneous tumours. SCID mice (n¼7/group) with established (B100mm
3) Hep3B tumour
xenografts were treated by intraperitoneal injection every 4 days for a total of four doses (red arrows) with the anti-CD133 antibody (AC133) or ADC
(AC133-vcMMAF) or isotype control mouse IgG1-vcMMAF. An additional group of mice was left untreated as a control. Median tumour volume plots were
continued for each group until one or more animals died or were euthanised (see Materials and methods). Tumours were collected when the tumour
volume reached 1000mm
3. Highly concordant data were in an independent replicate of this experiment. (B) CD133 expression in Hep3B xenograft
tumours after anti-CD133 drug conjugate treatment. IHC analysis using rabbit anti-CD133 MAb in (a) untreated Hep3B xenograft, (b) treatment with
control IgG-vcMMAF (3.0mgkg
 1) and (c) treated with AC133-vcMMAF (3.0mgkg
 1). (d) same tumour as (c) stained with control rabbit IgG as primary
antibody. Fast Red chromagen was used to detect CD133 expression.
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demonstrates that CD133 on the tumours is accessible to targeting
using an ADC.
CD133 is expressed in normal haematologic, neuronal, and
endothelial progenitor cells (Handgretinger et al, 2003; Larrivee
et al, 2005; Shmelkov et al, 2005). In a previous study, we
determined by quantitative flow cytometric analysis that the level
of CD133 in CD34-enriched normal bone marrow progenitor cells
is low (o5000 sites per cell) (Van Orden et al, submitted). We
tested normal CD34þ haematopoietic cells using bone marrow
colony formation assay, and as expected because bone marrow
progenitor cells are CD133þ, colony formation was inhibited by
AC133-vcMMAF. The most sensitive cells to the treatment were
CFU-GM (IC50o0.1mgml
 1) while CFU-GEMM, BFU-E, and CFU-E
were more resistant (IC50 of 5–10mgml
 1).
We also observed limited apical staining of normal epithelial
cells in biliary ducts of the pancreas and gastric glands of low to
moderate intensity. Interestingly, the apical nature of CD133
expression in normal human tissues may limit access to antibody
and thereby lower the risk of antigen-dependent toxicities. In
contrast, cell polarity of CD133 expression is lost for at least poorly
differentiated tumours, potentially enhancing the accessibility to
antibody targeting (Christiansen and Rajasekaran, 2004; Chris-
tiansen et al, 2005). Consistent with this notion is the observation
that Hep3B cells give rise to poorly differentiated tumours in vivo
whose growth is slowed by the anti-CD133 ADC, AC133-vcMMAF.
Hence, it may be desirable to target CD133þ tumours that are of
the poorly differentiated stage rather than well-differentiated
tumours with apically expressed CD133.
In previous studies in colorectal cancer, we showed that anti-
CD133 ADC can internalise upon binding to CD133 on the cell
surface and had cytotoxic and/or anti-proliferative activity against
four out of 10 colorectal cancer cell lines tested (Van Orden et al,
2008). Immunofluorescence microscopy was used to investigate
the internalisation and subcellular localisation of the ADC in both
sensitive and resistant cell lines. The ADC is able to efficiently
traffic to the lysosome where the linker can be cleaved in sensitive
cell lines such as Hep3B and KATO III. Hep3B cells have high
CD133 expression (66000 copies per cell). Moreover, substantial
accumulation of the ADC was detected inside the cell within 24h.
Although KATO III cells have more modest levels of CD133 (12000
copies per cell), colocalisation of the ADC within the lysosome was
detected, as well as efficient cell cytotoxicity in vitro. In contrast, in
Su.86.86 cells which were resistant to the cytotoxic effects of anti-
CD133-drug conjugate, the ADC colocalised to caveolae, not the
lysosomal compartments. We have previously observed such
differential ADC localisation in other sensitive and resistant cell
lines with ADCs targeting melanotransferin/p97 (Smith et al, 2006).
This may provide an additional level of drug specificity to ADCs.
CD133 expression in tumours can vary from only a subpopulation
of cells, which are putative cancer stem cells, to a significant
proportion (425%) of cancer cells within the tumour, indicating
that not all CD133-expressing cancer cells possess stem-like
properties. For tumours where CD133 expression is markedly high,
using an ADC may prove to be effective in preventing tumour
growth. We have shown that the anti-CD133 ADC, AC133-vcMMAF
can effectively delay CD133þ Hep3B tumour growth in vivo.
Targeting CD133þ tumour cells using ADCs has the potential to
eliminate CD133þ CSCs as well as antigen-positive tumour bulk.
In addition, due to the presence of non-CD133-expressing cells
in primary tumours, to optimise efficacy it may be necessary or
desirable to kill adjacent tumour cells that are not expressing
CD133. This might potentially be accomplished using ADCs with
bystander-killing capability (Kovtun et al, 2006). Alternatively,
ADCs could be combined with cytotoxic chemotherapy for de-
bulking and increasing target accessibility for the ADC. Indeed,
clinical benefit from combining an ADC with cytotoxic chemo-
therapy has recently been demonstrated. Specifically, addition of
the ADC, gemtuzumab ozogamicin (Mylotarg) to cytotoxic
chemotherapy increased the disease-free survival in a clinical trial
in acute myeloid leukaemia (Clavio et al, 2007). A recent study of
CD133-expressing tumour cells isolated from human glioma
xenografts and primary glioblastomas reported that the CD133þ
tumour cells may represent the population that confers glioma
radiation resistance (Bao et al, 2006). These cells preferentially
activate the DNA damage check point in response to radiation and
effectively repair radiation-induced DNA damage. This implies
that radiation therapy in combination with another therapy that
effectively targets the CD133þ tumour cells will be required to
eradicate the tumour. Anti-CD133 ADCs warrant further evalua-
tion as a therapeutic strategy to eradicate CD133þ tumour cells,
including cancer stem cells.
ACKNOWLEDGEMENTS
We acknowledge the technical assistance of Changpu Yu, David
Peckham and Ivan Stone, and thank Dr Jonathan Drachman for
critical review of the paper.
REFERENCES
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW,
Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by
preferential activation of the DNA damage response. Nature 444:
756–760
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:
730–737
Buhring HJ, Seiffert M, Marxer A, Weiss B, Faul C, Kanz L, Brugger W
(1999) AC133 antigen expression is not restricted to acute myeloid
leukemia blasts but is also found on acute lymphoid leukemia blasts and
on a subset of CD34þB-cell precursors. Blood 94: 832–833
Christiansen J, Rajasekaran AK (2004) Biological impediments to
monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther
3: 1493–1501
Christiansen JJ, Rajasekaran SA, Inge L, Cheng L, Anilkumar G, Bander NH,
Rajasekaran AK (2005) N-glycosylation and microtubule integrity are
involved in apical targeting of prostate-specific membrane antigen:
implications for immunotherapy. Mol Cancer Ther 4: 704–714
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J,
Weissman IL, Wahl GM (2006) Cancer stem cells–perspectives on
current status and future directions: AACR workshop on cancer stem
cells. Cancer Res 66: 9339–9344
Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, Balocco M,
Michelis G, Miglino M, Manna A, Balleari E, Carella AM, Sessarego M,
Van Lint MT, Bacigalupo A, Gobbi M (2007) Adding low-dose gemtuzumab
ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may
improve disease-free and overall survival in elderly patients with non-M3
acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial
and comparison with a historical cohort of patients. Br J Haematol 138:
186–195
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective
identification of tumorigenic prostate cancer stem cells. Cancer Res 65:
10946–10951
Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL,
Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD
(2006) Enhanced activity of monomethylauristatin F through
monoclonal antibody delivery: effects of linker technology on efficacy
and toxicity. Bioconjug Chem 17: 114–124
D o r o n i n aS O ,T o k iB E ,T o r g o vM Y ,M e n d e l s o h nB A ,C e r v e n yC G ,C h a c eD F ,
DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF,
CD133 in hepatocellular and gastric cancers
LM Smith et al
108
British Journal of Cancer (2008) 99(1), 100–109 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sMeyer DL, Senter PD (2003) Development of potent monoclonal antibody
auristatin conjugates for cancer therapy. Nat Biotechnol 21: 778–784
Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K,
Knipe JO, Lasch SJ, Trail PA (2002) Cathepsin B-labile dipeptide linkers
for lysosomal release of doxorubicin from internalizing immunoconju-
gates: model studies of enzymatic drug release and antigen-specific in
vitro anticancer activity. Bioconjug Chem 13: 855–869
Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB,
Corbeil D (2005) Prominin-1/CD133, a neural and hematopoietic stem
cell marker, is expressed in adult human differentiated cells and certain
types of kidney cancer. Cell Tissue Res 319: 15–26
Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF,
Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO,
Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-
monomethyl auristatin E conjugate with potent and selective antitumor
activity. Blood 102: 1458–1465
Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV (2002) Inhibition of
endosomal/lysosomal degradation increases the infectivity of human
immunodeficiency virus. J Virol 76: 11440–11446
Green CL, Loken M, Buck D, Deeg HJ (2000) Discordant expression of
AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and
acute myelogeneous leukemia (AML). Leukemia 14: 770–772
Handgretinger R, Gordon PR, Leimig T, Chen X, Buhring HJ, Niethammer
D, Kuci S (2003) Biology and plasticity of CD133+ hematopoietic stem
cells. Ann N Y Acad Sci 996: 141–151
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH,
Bronner-Fraser M, Kornblum HI (2003) Cancerous stem cells can arise
from pediatric brain tumors. Proc Natl Acad Sci U S A 100: 15178–15183
Hermann PC, Huber SL, Herrier T, Aicher A, Ellwart JW, Guba M,
Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells
determine tumor growth and metastatic activity in human pancreatic
cancer. Cell Stem Cell 1: 313–323
Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D, (1999) Expression
of AC133, a novel hematopoietic precursor antigen, on acute myeloid
leukemia cells. Blood 93: 1435–1437
Huff CA, Matsui W, Smith BD, Jones RJ (2006) The paradox of response
and survival in cancer therapeutics. Blood 107: 431–434
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer
statistics, 2008. CA Cancer J Clin 58: 71–96
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44
eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167–1174
Jones RJ, Matsui WH, Smith BD (2004) Cancer stem cells: are we missing
the target? J Natl Cancer Inst 96: 583–585
Jordan CT (2005) Targeting the most critical cells: approaching leukemia
therapy as a problem in stem cell biology. Nat Clin Pract Oncol 2: 224–225
Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA,
Chittenden T, Blattler WA, Goldmacher VS (2006) Antibody-drug
conjugates designed to eradicate tumors with homogeneous and hetero-
geneous expression of the target antigen. Cancer Res 66: 3214–3221
Larrivee B, Niessen K, Pollet I, Corbel SY, Long M, Rossi FM, Olive PL,
Karsan A (2005) Minimal contribution of marrow-derived endothelial
precursors to tumor vasculature. J Immunol 175: 2890–2899
Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer
DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF (2004)
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin
conjugates. Clin Cancer Res 10: 7842–7851
Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG,
Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E,
Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA,
Wood CG, Wahl AF (2006) Lymphocyte activation antigen CD70
expressed by renal cell carcinoma is a potential therapeutic target for
anti-CD70 antibody-drug conjugates. Cancer Res 66: 2328–2337
Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V, Langenfeld K,
Corbeil D, Huttner WB (2005) Release of extracellular membrane
particles carrying the stem cell marker prominin-1 (CD133) from neural
progenitors and other epithelial cells. J Cell Sci 118: 2849–2858
McMillian MK, Li L, Parker JB, Patel L, Zhong Z, Gunnett JW, Powers WJ,
Johnson MD (2002) An improved resazurin-based cytotoxicity assay for
hepatic cells. Cell Biol Toxicol 18: 157–173
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA,
Waller EK, Buck DW (1997) A novel five-transmembrane hematopoietic
stem cell antigen: isolation, characterization, and molecular cloning.
Blood 90: 5013–5021
Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L,
Andera L, Ralph SJ (2007) Tumour-initiating cells vs cancer ‘stem’ cells
and CD133: what’s in the name? Biochem Biophys Res Commun 355:
855–859
O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer
cell capable of initiating tumour growth in immunodeficient mice.
Nature 445: 106–110
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C,
De Maria R (2007) Identification and expansion of human colon cancer-
initiating cells. Nature 445: 111–115
Rizzo S, Attard G, Hudson DL (2005) Prostate epithelial stem cells. Cell
Prolif 38: 363–374
Shmelkov SV, St Clair R, Lyden D, Rafii S (2005) AC133/CD133/Prominin-
1. Int J Biochem Cell Biol 37: 715–719
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB
(2003) Identification of a cancer stem cell in human brain tumors.
Cancer Res 63: 5821–5828
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman
RM, Cusimano MD, Dirks PB (2004) Identification of human brain
tumour initiating cells. Nature 432: 396–401
Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ (2006) Potent
cytotoxicity of an auristatin-containing antibody-drug conjugate target-
ing melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther
5: 1474–1482
Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C,
Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL,
Wahl AF (2006) Lysosomal trafficking and cysteine protease metabolism
confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin
conjugates. J Biol Chem 281: 10540–10547
Tang C, Ang BT, Pervaiz S (2007) Cancer stem cell: target for anti-cancer
therapy. FASEB J 21: 3777–3785
Van Orden KL, Birse CE, He T, Smith LM, McKinnon K, Lee C, FitzHugh
W, Duniho S, Nesterova A, McCaffery I, Kim YJ, Aggarwal S, Mesmer D,
Carter PJ, Moore PA, Ruben SM. Proteomic analysis of colorectal tumors
identifies the cancer stem cell marker CD133/prominin-1 as a potential
therapeutic target (submitted)
Waller CF, Martens UM, Lange W (1999) Philadelphia chromosome-
positive cells are equally distributed in AC133þ and AC133  fractions
of CD34þ peripheral blood progenitor cells from patients with CML.
Leukemia 13: 1466–1467
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG,
Olweus J, Kearney J, Buck DW (1997) AC133, a novel marker for human
hematopoietic stem and progenitor cells. Blood 90: 5002–5012
CD133 in hepatocellular and gastric cancers
LM Smith et al
109
British Journal of Cancer (2008) 99(1), 100–109 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s